Lytix Biopharma presenting at major investor conferences in London and Stockholm in November

08 Nov 2023 12:00 CET

Oslo, 8 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo:
LYTIX), a clinical stage immuno-oncology company, announces that Dr Øystein
Rekdal, CEO, will deliver oral presentations to institutional investors in
London at the LSX Inv€$tival Showcase on the 13th of November, and attend the
Jefferies Healthcare Conference on the 14th -16th November.

Investors interested in meeting should get in contact through the event
partnering system or through the IR team.

Later in the month, on the 23rd of November, Dr Rekdal will give a presentation
at the Redeye Life Science Day 2023 in Stockholm. There he will answer questions
about the Company's latest positive developments, in particular, the preliminary
Phase II data recently presented at ESMO - into the use of LTX-315 for the
treatment of advanced melanoma.

The Redeye event can be watched live via the website
https://www.redeye.se/events/915984/redeye-life-science-day-2023 and via a
recording which will be made available afterwards.


Dr. Rekdal said: “We are looking forward to meeting with international investors
at these conferences, to further raise awareness of the progress we have made
with our unique approach to overcoming tumor heterogeneity by boosting a broad
T-cell response. In particular, I am looking forward to presenting the
encouraging preliminary clinical data that we announced at ESMO.”


***

For more information, please contact:
Gjest Breistein, CFO
E-Mail: gjest.breistein@lytixbiopharma.com

Optimum Strategic Communications
Nick Bastin, Jonathan Edwards
E-mail: lytix@optimumcomms.com


Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient’s immune system to fight cancer. The
Company’s technology is based on pioneering research in “host defense peptides”
– nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s
lead product, LTX-315, is a first-in-class molecule representing a new and
superior therapeutic principle to kill cancer cells and boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapies. LTX-315 targets cancer cells and disintegrates their
cell membranes, causing immunogenic cell death and release of a patient’s tumor
specific antigens. This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a US based, healthcare-focused investment firm.

More information:
Access the news on Oslo Bors NewsWeb site